home / stock / cfrx / cfrx news

CFRX News and Press, ContraFect Corporation From 01/06/22

Stock Information
Company Name: ContraFect Corporation
Stock Symbol: CFRX
Market: NASDAQ
Website: contrafect.com
Menu
CFRX CFRX Quote CFRX Short CFRX News CFRX Articles CFRX Message Board
Get CFRX Alerts

News, Short Squeeze, Breakout and More Instantly...
CFRX - ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis

YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...
CFRX - Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases

YONKERS, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...

CFRX - Contrafect EPS beats by $0.15

Contrafect (NASDAQ:CFRX): Q3 GAAP EPS of -$0.13 beats by $0.15. Cash, cash equivalents and marketable securities of $63.3M. Press Release For further details see: Contrafect EPS beats by $0.15

CFRX - ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for th...
CFRX - ContraFect's New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis

YONKERS, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...

CFRX - ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients

YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces it will be presentin...

CFRX - ContraFect's New Phase 2 Exebacase Data Presented at IDWeekTM Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia

YONKERS, New York, Oct. 04, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the...
CFRX - Wall Street Breakfast: The Week Ahead (Podcast)

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

CFRX - Catalyst watch for next week: GM, Box and IBM events, Altria drama and auto prices watch

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CFRX - ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek(TM) 2021

YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the tr...
Previous 10 Next 10